Skip to content

Released Mar 26, 2026, after the close

10-K filed Mar 26, 2026, 85 days after period end · 0001683168-26-002257

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$4.55MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$4,688,473N/M
Operating Cash Flowderived-$3,736,043N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figures
Net Income-$4.55M-$6.45M-$7.61M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR